Tapewire

Nasdaq · USD

ISRG

INTUITIVE SURGICAL INC

Export transactions ↓
Tapewire entity
2878
SEC CIK
0001035267
Parsed reports
1,605

Last 12 months

Inside the activity.

0 purchase rows · 74 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 2025011
Dec 202507
Jan 202606
Feb 202606
Mar 202609
Apr 202602
May 202606
Jun 202607
Jul 202605
Aug 202609
Sep 202606
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
February 10, 2026 Filed Feb 11, 2026 22:17 UTC
Widman FredrikVP Corporate Controller
Exercise / conversionRestricted Stock Units · Derivative 567 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001897970-26-000002 · edgardoc.xml · derivative · entry 4

Widman Fredrik · CIK 0001897970 · VP Corporate Controller

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 567

Underlying: Common Stock · 567 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock upon vesting. 25% of the RSUs shall vest on each anniversary of February 10, 2023, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

F3 · derivative.expiration_date: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock upon vesting. 25% of the RSUs shall vest on each anniversary of February 10, 2023, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

Read SEC document
February 10, 2026 Filed Feb 11, 2026 22:17 UTC
Widman FredrikVP Corporate Controller
Tax withholdingCommon Stock 302 $492.84 $148,837.68
Disclosure

SEC source: 0001897970-26-000002 · edgardoc.xml · nonDerivative · entry 2

Widman Fredrik · CIK 0001897970 · VP Corporate Controller

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 793

F1 · kind: RSUs vest 25% per year over a four year period, commencing on each anniversary of February 10, 2023. RSUs convert into common stock on the vest date on a one-for-one basis. 25% of the shares have been released and a portion of the shares were held back to cover the statutory tax withholding requirements. The net shares were deposited into the holders account.

Read SEC document
February 10, 2026 Filed Feb 11, 2026 22:17 UTC
Widman FredrikVP Corporate Controller
Exercise / conversionCommon Stock 567 $0.00 $0.00
Disclosure

SEC source: 0001897970-26-000002 · edgardoc.xml · nonDerivative · entry 1

Widman Fredrik · CIK 0001897970 · VP Corporate Controller

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,095

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: RSUs vest 25% per year over a four year period, commencing on each anniversary of February 10, 2023. RSUs convert into common stock on the vest date on a one-for-one basis. 25% of the shares have been released and a portion of the shares were held back to cover the statutory tax withholding requirements. The net shares were deposited into the holders account.

Read SEC document
January 29, 2026 Filed Jan 31, 2026 02:45 UTC OtherCommon Stock 369 $0.00 $0.00
Disclosure

SEC source: 0001416180-26-000002 · edgardoc.xml · nonDerivative · entry 1

Leonard Keith R · CIK 0001416180 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 370

F1 · kind: Transfer of shares pursuant to divorce decree.

Read SEC document
January 29, 2026 Filed Jan 31, 2026 02:16 UTC
Curet MyriamEVP & Chief Medical Officer
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 126 $0.00 Strike: $208.90 $0.00
Disclosure

SEC source: 0001632901-26-000004 · edgardoc.xml · derivative · entry 4

Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 125

Underlying: Common Stock · 126 shares

Expires 2029-08-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026.

F2 · derivative.exercise_date: Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. Option shall vest 7/48 one month after the date of grant and 1/48 each month thereafter.

Read SEC document
January 29, 2026 Filed Jan 31, 2026 02:16 UTC
Curet MyriamEVP & Chief Medical Officer
SaleCommon Stock 126 $520.02 $65,522.52
Disclosure

SEC source: 0001632901-26-000004 · edgardoc.xml · nonDerivative · entry 2

Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026.

Read SEC document
January 29, 2026 Filed Jan 31, 2026 02:16 UTC
Curet MyriamEVP & Chief Medical Officer
Exercise / conversionCommon Stock 126 $208.90 $26,321.40
Disclosure

SEC source: 0001632901-26-000004 · edgardoc.xml · nonDerivative · entry 1

Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 126

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026.

Read SEC document
January 28, 2026 Filed Jan 31, 2026 02:12 UTC GrantPerformance Stock Units - 2-28-2023 · Derivative 17,556 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001280628-26-000004 · edgardoc.xml · derivative · entry 2

GUTHART GARY S · CIK 0001280628 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,556

Underlying: Common Stock · 17,556 shares

Expires not disclosed

F2 · derivative.exercise_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

F2 · derivative.expiration_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

Read SEC document
January 28, 2026 Filed Jan 31, 2026 02:12 UTC GrantPerformance Stock Units - 2-26-2024 · Derivative 8,267 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001280628-26-000004 · edgardoc.xml · derivative · entry 1

GUTHART GARY S · CIK 0001280628 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,267

Underlying: Common Stock · 8,267 shares

Expires not disclosed

F1 · derivative.exercise_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 26, 2024 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 26, 2027, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

F1 · derivative.expiration_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 26, 2024 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 26, 2027, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

Read SEC document
January 28, 2026 Filed Jan 31, 2026 02:03 UTC
Samath JamieEVP & CFO & Enterprise Technol
GrantPerformance Stock Units - 2-28-2023 · Derivative 7,182 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001330269-26-000002 · edgardoc.xml · derivative · entry 2

Samath Jamie · CIK 0001330269 · EVP & CFO & Enterprise Technol

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,182

Underlying: Common Stock · 7,182 shares

Expires not disclosed

F2 · derivative.exercise_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

F2 · derivative.expiration_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

Read SEC document
January 28, 2026 Filed Jan 31, 2026 02:03 UTC
Samath JamieEVP & CFO & Enterprise Technol
GrantPerformance Stock Units - 2-26-2024 · Derivative 3,180 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001330269-26-000002 · edgardoc.xml · derivative · entry 1

Samath Jamie · CIK 0001330269 · EVP & CFO & Enterprise Technol

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,180

Underlying: Common Stock · 3,180 shares

Expires not disclosed

F1 · derivative.exercise_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 26, 2024 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 26, 2027, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

F1 · derivative.expiration_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 26, 2024 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 26, 2027, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

Read SEC document
January 28, 2026 Filed Jan 31, 2026 02:20 UTC
Rosa David J.Director · Chief Executive Officer (CEO)
GrantPerformance Stock Units - 6-12-2023 · Derivative 6,034 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001519593-26-000002 · edgardoc.xml · derivative · entry 3

Rosa David J. · CIK 0001519593 · Director · Chief Executive Officer (CEO)

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,034

Underlying: Common Stock · 6,034 shares

Expires not disclosed

F3 · derivative.exercise_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on June 12, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28. 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

F3 · derivative.expiration_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on June 12, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28. 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

Read SEC document
January 28, 2026 Filed Jan 31, 2026 02:20 UTC
Rosa David J.Director · Chief Executive Officer (CEO)
GrantPerformance Stock Units - 2-28-2023 · Derivative 9,575 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001519593-26-000002 · edgardoc.xml · derivative · entry 2

Rosa David J. · CIK 0001519593 · Director · Chief Executive Officer (CEO)

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,575

Underlying: Common Stock · 9,575 shares

Expires not disclosed

F2 · derivative.exercise_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

F2 · derivative.expiration_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

Read SEC document
January 28, 2026 Filed Jan 31, 2026 02:20 UTC
Rosa David J.Director · Chief Executive Officer (CEO)
GrantPerformance Stock Units - 2-26-2024 · Derivative 6,360 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001519593-26-000002 · edgardoc.xml · derivative · entry 1

Rosa David J. · CIK 0001519593 · Director · Chief Executive Officer (CEO)

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,360

Underlying: Common Stock · 6,360 shares

Expires not disclosed

F1 · derivative.exercise_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 26, 2024 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 26, 2027, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

F1 · derivative.expiration_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 26, 2024 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 26, 2027, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

Read SEC document
January 28, 2026 Filed Jan 31, 2026 02:24 UTC
LOEB GARYEVP & Chief Legal and Complian
GrantPerformance Stock Units - 2-28-2023 · Derivative 2,098 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001561733-26-000002 · edgardoc.xml · derivative · entry 2

LOEB GARY · CIK 0001561733 · EVP & Chief Legal and Complian

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,098

Underlying: Common Stock · 2,098 shares

Expires not disclosed

F2 · derivative.exercise_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

F2 · derivative.expiration_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

Read SEC document
January 28, 2026 Filed Jan 31, 2026 02:24 UTC
LOEB GARYEVP & Chief Legal and Complian
GrantPerformance Stock Units - 2-26-2024 · Derivative 2,543 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001561733-26-000002 · edgardoc.xml · derivative · entry 1

LOEB GARY · CIK 0001561733 · EVP & Chief Legal and Complian

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,543

Underlying: Common Stock · 2,543 shares

Expires not disclosed

F1 · derivative.exercise_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 26, 2024 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 26, 2027, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

F1 · derivative.expiration_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 26, 2024 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 26, 2027, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

Read SEC document
January 28, 2026 Filed Jan 31, 2026 02:16 UTC
Curet MyriamEVP & Chief Medical Officer
GrantPerformance Stock Units - 2-28-2023 · Derivative 5,585 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001632901-26-000004 · edgardoc.xml · derivative · entry 5

Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,585

Underlying: Common Stock · 5,585 shares

Expires not disclosed

F3 · derivative.exercise_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

F3 · derivative.expiration_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

Read SEC document
January 28, 2026 Filed Jan 31, 2026 02:08 UTC
Charlton Henry LEVP & Chief Commercial and Mkt
GrantPerformance Stock Units - 2-28-2023 · Derivative 7,182 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001897642-26-000002 · edgardoc.xml · derivative · entry 2

Charlton Henry L · CIK 0001897642 · EVP & Chief Commercial and Mkt

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,182

Underlying: Common Stock · 7,182 shares

Expires not disclosed

F2 · derivative.exercise_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

F2 · derivative.expiration_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

Read SEC document
January 28, 2026 Filed Jan 31, 2026 02:08 UTC
Charlton Henry LEVP & Chief Commercial and Mkt
GrantPerformance Stock Units - 2-26-2024 · Derivative 2,861 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001897642-26-000002 · edgardoc.xml · derivative · entry 1

Charlton Henry L · CIK 0001897642 · EVP & Chief Commercial and Mkt

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,861

Underlying: Common Stock · 2,861 shares

Expires not disclosed

F1 · derivative.exercise_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 26, 2024 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 26, 2027, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

F1 · derivative.expiration_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 26, 2024 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 26, 2027, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

Read SEC document
January 28, 2026 Filed Jan 31, 2026 02:28 UTC
Brosius MarkSVP & Chief Mfg and Supply Cha
GrantPerformance Stock Units - 2-28-2023 · Derivative 5,585 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0002010300-26-000003 · edgardoc.xml · derivative · entry 2

Brosius Mark · CIK 0002010300 · SVP & Chief Mfg and Supply Cha

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,585

Underlying: Common Stock · 5,585 shares

Expires not disclosed

F2 · derivative.exercise_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

F2 · derivative.expiration_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

Read SEC document
January 28, 2026 Filed Jan 31, 2026 02:28 UTC
Brosius MarkSVP & Chief Mfg and Supply Cha
GrantPerformance Stock Units - 2-26-2024 · Derivative 2,702 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0002010300-26-000003 · edgardoc.xml · derivative · entry 1

Brosius Mark · CIK 0002010300 · SVP & Chief Mfg and Supply Cha

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,702

Underlying: Common Stock · 2,702 shares

Expires not disclosed

F1 · derivative.exercise_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 26, 2024 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 26, 2027, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

F1 · derivative.expiration_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 26, 2024 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 26, 2027, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

Read SEC document
January 27, 2026 Filed Jan 28, 2026 21:20 UTC Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 25,500 $0.00 Strike: $174.26 $0.00
Disclosure

SEC source: 0001280628-26-000002 · edgardoc.xml · derivative · entry 6

GUTHART GARY S · CIK 0001280628 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,500 shares

Expires 2028-08-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 28, 2026.

F5 · derivative.exercise_date: Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. Option shall vest 7/48 one month after the date of grant and 1/48 each month thereafter.

Read SEC document
January 27, 2026 Filed Jan 28, 2026 21:20 UTC SaleCommon Stock 1,400 $531.52 $744,129.12
Disclosure

SEC source: 0001280628-26-000002 · edgardoc.xml · nonDerivative · entry 4

GUTHART GARY S · CIK 0001280628 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · Trust FBO Son

Disclosed balance after: 15,720

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 28, 2026.

F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $529.77 to $534.00 as follows: 520 shares sold at $529.77 to $530.61; 360 shares sold at $530.98 to $531.86; 240 shares sold at $532.05 to $532.61; and 280 shares sold at $533.82 to $534.00. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
January 27, 2026 Filed Jan 28, 2026 21:20 UTC SaleCommon Stock 1,400 $531.53 $744,139.90
Disclosure

SEC source: 0001280628-26-000002 · edgardoc.xml · nonDerivative · entry 3

GUTHART GARY S · CIK 0001280628 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · Trust FBO Daughter

Disclosed balance after: 15,720

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 28, 2026.

F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $529.77 to $534.00 as follows: 520 shares sold at $529.77 to $530.61; 298 shares sold at $530.98 to $531.87; 302 shares sold at $532.05 to $532.61; and 280 shares sold at $533.82 to $534.00. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
January 27, 2026 Filed Jan 28, 2026 21:20 UTC SaleCommon Stock 24,500 $530.10 $12,987,403.45
Disclosure

SEC source: 0001280628-26-000002 · edgardoc.xml · nonDerivative · entry 2

GUTHART GARY S · CIK 0001280628 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,694

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 28, 2026.

F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $525.51 to $534.00 as follows: 2,500 shares sold at $525.51 to $525.71; 280 shares sold at $526.94 to $527.41; 2,252 shares sold at $528.23 to $529.18; 9,860 shares sold at $529.27 to $530.27; 3,475 shares sold at $530.29 to $531.22; 1,589 shares sold at $531.37 to $532.24; 3,704 shares sold at $532.53 to $533.41; and 840 shares sold at $533.82 to $534.00. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
January 27, 2026 Filed Jan 28, 2026 21:20 UTC Exercise / conversionCommon Stock 25,500 $174.26 $4,443,545.85
Disclosure

SEC source: 0001280628-26-000002 · edgardoc.xml · nonDerivative · entry 1

GUTHART GARY S · CIK 0001280628 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 28,194

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 28, 2026.

Read SEC document
January 27, 2026 Filed Jan 28, 2026 21:34 UTC
Curet MyriamEVP & Chief Medical Officer
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 105 $0.00 Strike: $229.39 $0.00
Disclosure

SEC source: 0001632901-26-000002 · edgardoc.xml · derivative · entry 7

Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,362

Underlying: Common Stock · 105 shares

Expires 2030-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026.

F3 · derivative.exercise_date: 12.5% of the shares subject to the option vest on the six-month anniversary measured from February 10, 2023, and 1/48th of the total number of shares vest in forty-two (42) successive and equal monthly installments thereafter, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

Read SEC document
January 27, 2026 Filed Jan 28, 2026 21:34 UTC
Curet MyriamEVP & Chief Medical Officer
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 125 $0.00 Strike: $208.90 $0.00
Disclosure

SEC source: 0001632901-26-000002 · edgardoc.xml · derivative · entry 6

Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 251

Underlying: Common Stock · 125 shares

Expires 2029-08-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026.

F2 · derivative.exercise_date: Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. Option shall vest 7/48 one month after the date of grant and 1/48 each month thereafter.

Read SEC document
January 27, 2026 Filed Jan 28, 2026 21:34 UTC
Curet MyriamEVP & Chief Medical Officer
SaleCommon Stock 125 $532.61 $66,576.25
Disclosure

SEC source: 0001632901-26-000002 · edgardoc.xml · nonDerivative · entry 4

Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026.

Read SEC document
January 27, 2026 Filed Jan 28, 2026 21:34 UTC
Curet MyriamEVP & Chief Medical Officer
Exercise / conversionCommon Stock 125 $208.90 $26,112.50
Disclosure

SEC source: 0001632901-26-000002 · edgardoc.xml · nonDerivative · entry 3

Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 125

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026.

Read SEC document
January 27, 2026 Filed Jan 28, 2026 21:34 UTC
Curet MyriamEVP & Chief Medical Officer
SaleCommon Stock 105 $532.61 $55,924.05
Disclosure

SEC source: 0001632901-26-000002 · edgardoc.xml · nonDerivative · entry 2

Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026.

Read SEC document
January 27, 2026 Filed Jan 28, 2026 21:34 UTC
Curet MyriamEVP & Chief Medical Officer
Exercise / conversionCommon Stock 105 $229.39 $24,085.95
Disclosure

SEC source: 0001632901-26-000002 · edgardoc.xml · nonDerivative · entry 1

Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026.

Read SEC document
December 15, 2025 Filed Dec 15, 2025 23:52 UTC
Brosius MarkSVP & Chief Mfg and Supply Cha
SaleCommon Stock 464 $548.49 $254,499.36
Disclosure

SEC source: 0002010300-25-000004 · edgardoc.xml · nonDerivative · entry 3

Brosius Mark · CIK 0002010300 · SVP & Chief Mfg and Supply Cha

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 443

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.

Read SEC document
December 15, 2025 Filed Dec 17, 2025 23:59 UTC
Brosius MarkSee Remarks
SaleCommon Stock 464 $548.49 $254,499.36
Disclosure

SEC source: 0001610717-25-000419 · form4.xml · nonDerivative · entry 1

Brosius Mark · CIK 0002010300 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 131

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.

Read SEC document
December 12, 2025 Filed Dec 15, 2025 23:52 UTC
Brosius MarkSVP & Chief Mfg and Supply Cha
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 4,500 $0.00 Strike: $79.64 $0.00
Disclosure

SEC source: 0002010300-25-000004 · edgardoc.xml · derivative · entry 4

Brosius Mark · CIK 0002010300 · SVP & Chief Mfg and Supply Cha

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,500 shares

Expires 2027-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.

F2 · derivative.exercise_date: Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. The option vests 1/8th six months after the date of grant and 1/48th monthly thereafter.

Read SEC document
December 12, 2025 Filed Dec 15, 2025 23:52 UTC
Brosius MarkSVP & Chief Mfg and Supply Cha
SaleCommon Stock 4,500 $547.36 $2,463,120.00
Disclosure

SEC source: 0002010300-25-000004 · edgardoc.xml · nonDerivative · entry 2

Brosius Mark · CIK 0002010300 · SVP & Chief Mfg and Supply Cha

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 907

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.

Read SEC document
December 12, 2025 Filed Dec 15, 2025 23:52 UTC
Brosius MarkSVP & Chief Mfg and Supply Cha
Exercise / conversionCommon Stock 4,500 $79.64 $358,370.10
Disclosure

SEC source: 0002010300-25-000004 · edgardoc.xml · nonDerivative · entry 1

Brosius Mark · CIK 0002010300 · SVP & Chief Mfg and Supply Cha

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,407

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.

Read SEC document
December 12, 2025 Filed Dec 17, 2025 23:43 UTC Amendment
Brosius MarkSee Remarks
SaleCommon Stock 312 $547.36 $170,776.32
Disclosure

SEC source: 0001610717-25-000418 · form4.xml · nonDerivative · entry 1

Brosius Mark · CIK 0002010300 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 595

F2 · date: The third transaction line in Table I of the Form 4 filed by the Reporting Person on 12/15/2025 incorrectly reported the transaction details. The transaction line as reported herein has been restated to correct the errors in the original Form 4. Except as otherwise noted in this footnote, all other information disclosed in the Reporting Person's original Form 4 was accurately reported.

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.

F2 · shares: The third transaction line in Table I of the Form 4 filed by the Reporting Person on 12/15/2025 incorrectly reported the transaction details. The transaction line as reported herein has been restated to correct the errors in the original Form 4. Except as otherwise noted in this footnote, all other information disclosed in the Reporting Person's original Form 4 was accurately reported.

F2 · price: The third transaction line in Table I of the Form 4 filed by the Reporting Person on 12/15/2025 incorrectly reported the transaction details. The transaction line as reported herein has been restated to correct the errors in the original Form 4. Except as otherwise noted in this footnote, all other information disclosed in the Reporting Person's original Form 4 was accurately reported.

F2 · balance_after: The third transaction line in Table I of the Form 4 filed by the Reporting Person on 12/15/2025 incorrectly reported the transaction details. The transaction line as reported herein has been restated to correct the errors in the original Form 4. Except as otherwise noted in this footnote, all other information disclosed in the Reporting Person's original Form 4 was accurately reported.

Read SEC document
December 10, 2025 Filed Dec 10, 2025 23:23 UTC
Curet MyriamEVP & Chief Medical Officer
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 104 $0.00 Strike: $229.39 $0.00
Disclosure

SEC source: 0001632901-25-000010 · edgardoc.xml · derivative · entry 4

Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,467

Underlying: Common Stock · 104 shares

Expires 2030-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026.

F2 · derivative.exercise_date: 12.5% of the shares subject to the option vest on the six-month anniversary measured from February 10, 2023, and 1/48th of the total number of shares vest in forty-two (42) successive and equal monthly installments thereafter, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

Read SEC document
December 10, 2025 Filed Dec 10, 2025 23:23 UTC
Curet MyriamEVP & Chief Medical Officer
SaleCommon Stock 104 $559.90 $58,229.60
Disclosure

SEC source: 0001632901-25-000010 · edgardoc.xml · nonDerivative · entry 2

Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026.

Read SEC document
December 10, 2025 Filed Dec 10, 2025 23:23 UTC
Curet MyriamEVP & Chief Medical Officer
Exercise / conversionCommon Stock 104 $229.39 $23,856.56
Disclosure

SEC source: 0001632901-25-000010 · edgardoc.xml · nonDerivative · entry 1

Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 104

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026.

Read SEC document
December 01, 2025 Filed Dec 2, 2025 17:50 UTC
GUTHART GARY SDirector · Executive Chair of the Board o
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 25,500 $0.00 Strike: $139.52 $0.00
Disclosure

SEC source: 0001280628-25-000006 · edgardoc.xml · derivative · entry 6

GUTHART GARY S · CIK 0001280628 · Director · Executive Chair of the Board o

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,500 shares

Expires 2028-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 28, 2026.

F3 · derivative.exercise_date: Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. The option vests 1/8th six months after the date of grant and 1/48th monthly thereafter.

Read SEC document
December 01, 2025 Filed Dec 2, 2025 17:50 UTC
GUTHART GARY SDirector · Executive Chair of the Board o
SaleCommon Stock 22,806 $570.89 $13,019,721.90
Disclosure

SEC source: 0001280628-25-000006 · edgardoc.xml · nonDerivative · entry 2

GUTHART GARY S · CIK 0001280628 · Director · Executive Chair of the Board o

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,694

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 28, 2026.

F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $568.62 to $573.54 as follows: 5,550 shares sold at $568.62 to $569.62; 6,304 shares sold at $569.64 to $570.63; 2,285 shares sold at $570.66 to $571.61; 5,528 shares sold at $571.70 to $572.70; 3,139 shares sold at $572.72 to $573.54. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
December 01, 2025 Filed Dec 2, 2025 17:50 UTC
GUTHART GARY SDirector · Executive Chair of the Board o
Exercise / conversionCommon Stock 25,500 $139.52 $3,557,760.00
Disclosure

SEC source: 0001280628-25-000006 · edgardoc.xml · nonDerivative · entry 1

GUTHART GARY S · CIK 0001280628 · Director · Executive Chair of the Board o

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 28, 2026.

Read SEC document
December 01, 2025 Filed Dec 2, 2025 21:16 UTC
Curet MyriamEVP & Chief Medical Officer
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 125 $0.00 Strike: $208.90 $0.00
Disclosure

SEC source: 0001632901-25-000008 · edgardoc.xml · derivative · entry 4

Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 376

Underlying: Common Stock · 125 shares

Expires 2029-08-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026.

F2 · derivative.exercise_date: Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. Option shall vest 7/48 one month after the date of grant and 1/48 each month thereafter.

Read SEC document
December 01, 2025 Filed Dec 2, 2025 21:16 UTC
Curet MyriamEVP & Chief Medical Officer
SaleCommon Stock 125 $568.99 $71,123.75
Disclosure

SEC source: 0001632901-25-000008 · edgardoc.xml · nonDerivative · entry 2

Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026.

Read SEC document
December 01, 2025 Filed Dec 2, 2025 21:16 UTC
Curet MyriamEVP & Chief Medical Officer
Exercise / conversionCommon Stock 125 $208.90 $26,112.50
Disclosure

SEC source: 0001632901-25-000008 · edgardoc.xml · nonDerivative · entry 1

Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 125

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026.

Read SEC document
November 12, 2025 Filed Nov 13, 2025 18:46 UTC Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 750 $0.00 Strike: $71.32 $0.00
Disclosure

SEC source: 0001277620-25-000008 · edgardoc.xml · derivative · entry 4

BARRATT CRAIG H · CIK 0001277620 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 750 shares

Expires 2026-04-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 29, 2026.

F2 · derivative.exercise_date: Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant or at the next Shareholders Meeting, whichever should take place first, provided that vesting will cease on termination of the Directors service to the Company.

Read SEC document
November 12, 2025 Filed Nov 13, 2025 18:46 UTC SaleCommon Stock 750 $580.00 $435,000.00
Disclosure

SEC source: 0001277620-25-000008 · edgardoc.xml · nonDerivative · entry 2

BARRATT CRAIG H · CIK 0001277620 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 29, 2026.

Read SEC document
November 12, 2025 Filed Nov 13, 2025 18:46 UTC Exercise / conversionCommon Stock 750 $71.32 $53,492.48
Disclosure

SEC source: 0001277620-25-000008 · edgardoc.xml · nonDerivative · entry 1

BARRATT CRAIG H · CIK 0001277620 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 750

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 29, 2026.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.